Answers are grounded in this paper and cite their sources.
The Mpox virus (previously termed monkeypox) was a relatively obscure zoonotic infection mainly confined to West and Central Africa with the notable exception of a 2003 outbreak in the United States associated with exotic pets. In the summer of 2022, however, the United States experienced an unexpected and unprecedented surge in cases with a markedly different clinical presentation. This epidemic appeared to be driven by close/intimate contact and evidenced a more varied clinical presentation easily confused with common sexually transmitted infections.1 While still navigating the COVID-19 pandemic, public health services launched education campaigns designed to raise awareness and mitigate risks of infection, educate the public and medical community on modes of transmission and the new clinical presentations, and minimize stigma. These education campaigns did influence behavior changes in some members of high-risk communities that led to decreased infections.2 The other major intervention was the release of the JYNNEOS vaccine, which has proven to lower the risk of Mpox infection.3 This vaccination campaign was launched at a time of decreased vaccine confidence4 stemming in part from the continued politicization of the COVID-19 vaccination recommendations. The success of the Mpox vaccine campaign is thus even more impressive and deserving of study to potentially provide a roadmap of combating vaccine hesitancy. “Mpox knowledge and vaccine willingness among a representative analysis of adults in Pennsylvania” in the issue uses a broad-ranging survey to examine Pennsylvania residents' knowledge of Mpox, perception of risk, and willingness to accept vaccine. The survey was conducted in September 2022 reflecting a period after the intensive education campaigns began. Less than 15% of the 1039 survey participants reported no knowledge of Mpox symptoms or transmission modalities reflecting wide penetrance of the education initiatives. The knowledge did appear more basic and the authors point out lacing a “nuanced understanding specific to the current outbreak.”5 Although the majority of survey participants considered themselves to be at low or no risk, those who did perceive increased risk were significantly more likely to plan to accept vaccine. Men who have sex with men comprised 7.2% of the respondents, well represented across age groups, and were more likely to have Mpox awareness/knowledge and acceptance of vaccination. These findings are consistent with the Centers for Disease Control and Prevention's Monkeypox State of Vaccine Confidence Report6 and represent a “dose-response” relationship between perception of Mpox risk and acceptance of vaccine.5 A finding that bears more study involves the health disparities in vaccination rates. Black and Hispanic populations were disproportionally affected in this epidemic yet received relatively fewer vaccines, even in high-risk groups such as those with a recent sexually transmitted infection.7–9 Pinto et al showed Black, non-Hispanic respondents were more likely to report wiliness to vaccinate. This argues against vaccine hesitancy as a reason for undervaccination and should be understood as a call to investigate hidden sources of bias decreasing vaccine rates. To date, the United States has experienced 31,010 cases and 55 deaths due to Mpox.10 Although cases have dropped, there remains a risk of resurgence of this infection. The willingness and ability to receive Mpox vaccine will be a significant modifier of future outbreaks. These data may also be generalizable to other instances of vaccine hesitancy and can further the investigations in health disparities.
No takes yet. Share an insight, caveat, or question.
David Cennimo (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: